- The disease
- The trial covers several related blood cancers in which B-cells — a type of white blood cell — become malignant. Non-Hodgkin lymphoma, B-cell ALL, CLL, and SLL are all diseases where the cancer cells carry a surface protein called CD19. Patients enrolled have relapsed (disease returned after prior treatment) or are refractory (disease did not respond to prior treatment) (per ClinicalTrials.gov NCT03666000). These are settings where standard therapies have already failed and treatment options are limited.
- What the asset is trying to do
- Azer-cel (also referred to as PBCAR0191) is an allogeneic CAR-T (chimeric antigen receptor T-cell) therapy, meaning the T-cells come from a healthy donor rather than from each individual patient. The cells are engineered to carry a receptor targeting CD19, a protein found on the surface of the malignant B-cells in these cancers. Because the cells are manufactured in batches from donor material rather than from each patient, the product can in principle be stored and administered without the per-patient manufacturing wait required for autologous (patient-derived) CAR-T therapies. Allogeneic products require additional genetic modifications to reduce the risk of the donor cells attacking the patient or being rejected by the patient's immune system.
- What the trial is measuring, and why it matters
- The primary objective of NCT03666000 is to evaluate the safety of azer-cel, consistent with a Phase 1 design that begins with dose escalation (per ClinicalTrials.gov NCT03666000). A recent announcement noted the enrolment of the first patient in a BTKi (Bruton's tyrosine kinase inhibitor) combination cohort, indicating the study also includes a cohort combining azer-cel with a BTKi (per Imugene ASX announcement, 27 May 2026). Safety endpoints in early oncology trials typically include the rate and severity of adverse events, with efficacy measures such as response rates collected as secondary or exploratory data.
- Efficacy benchmarks in this setting
- In autologous CD19 CAR-T therapies approved for r/r large B-cell lymphoma, complete response (CR) rates reported in registration trials include approximately 40% for axicabtagene ciloleucel (per Neelapu et al, NEJM 2017) and approximately 40% for tisagenlecleucel (per Schuster et al, NEJM 2019). For r/r CLL, no CAR-T therapy is currently approved; standard approved options include BTK inhibitors and venetoclax-based regimens. No allogeneic CD19 CAR-T product has received regulatory approval as of the date of these source materials (per the mechanism class profile, accessed 2026-05-04, ClinicalTrials.gov ALPHA2 NCT04416984). Figures from early-phase, non-randomised trials of any allogeneic CAR-T, including azer-cel, are not statistically comparable to response rates from pivotal trials of approved therapies.